Policy
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Recipharm, the contract development and manufacturing organisation, has achieved the new ISO 45001 certification at its Wasserburg facility in Germany.
As a student at a private school in Houston, Elizabeth Holmes had a reputation for being determined to accomplish her goals, no matter if she came in dead last. She was also notoriously private about her life.
With its concerns over drug pricing and potential questions of “pay-to-play” for access to the White House, Congress did not miss the chance to question President Donald Trump’s former attorney about his relationship with Novartis.
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces the filing of its 2018 Registration Document with the Autorité des marchés financiers.
NOXXON Pharma N.V. announced that it has filed the clinical trial application (CTA) with the Federal Institute for Drugs and Medical Devices, to start a Phase 1/2 clinical trial combining NOX-A12 with radiotherapy to treat newly diagnosed brain cancer patients who would not benefit from the current standard of care and whose tumor cannot be fully resected by surgery.
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Could a product in a weed killer contribute to the development of a cancer? That is the question a jury will answer as Bayer faces accusations that glyphosate, the active ingredient in its top=selling weed killer Roundup, caused cancer in some individuals who have used the product.
Shares of Adamis Pharmaceuticals are down nearly 5 percent this morning after the company announced late Tuesday that the U.S. Food and Drug Administration rejected its sublingual tadalafil product for erectile dysfunction, an alternative to the blockbuster Cialis.
FDA Commissioner Scott Gottlieb said the agency has changed its approach to the opioid crisis and will take a more aggressive approach on regulatory actions.